CARMIEL, Israel, March 17 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that it has initiated a phase I clinical trial of ...
CARMIEL, Israel, March 17 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results